Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer.
Luis D Borrero-García, Maria Del Mar Maldonado, Julia Medina-Velázquez...
https://pubmed.ncbi.nlm.nih.gov/34074257/Actively Recruiting
Led by MBQ Pharma · Updated on 2026-08-31
48
Participants Needed
4
Research Sites
N/A
Total Duration
Researchers are evaluating MBQ-167, an oral drug, in a Phase 1 clinical trial for participants with advanced breast cancer who have not responded to or cannot tolerate standard treatments. The study aims to find the maximum tolerated dose, understand side effects, determine how the drug is processed in the body, and assess whether it can slow, stop, or eliminate cancer. Participants will take MBQ-167 capsules twice daily with meals, starting with doses ranging from 10mg to 400mg following a dose-escalation design. They will take the drug for at least 21 days and may continue if it is safe and effective. The study includes multiple visits for evaluations, laboratory tests, and diary reviews throughout treatment and after stopping the drug. During the trial, participants will provide informed consent and be monitored closely with physical exams and lab tests. Researchers will measure the maximum tolerated dose over 21 days and study drug levels and gene expression changes over up to 56 days. Safety and treatment effects will be tracked until the participant stops the drug or the study ends, with total participation lasting until December 2026 or earlier if discontinued.
CONDITIONS
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
S
Scott Houston
J
Jose Rodriguez-Orengo, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
MBQ Pharma
Lead Sponsor
Congressionally Directed Medical Research Programs
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | MBQ‑167 (investigational) | Guideline‑recommended care (context) |
|---|---|---|
| What it is | An oral inhibitor targeting the Rac and Cdc42 GTPases evaluated in a sequential dose‑escalation regimen for advanced breast cancer after standard treatments have failed | Depending on tumor biology, current standard care includes systemic therapies guided by biomarker status and prior lines of treatment, as defined in recent international and national guidelines |
| Primary use | Evaluated to establish maximum tolerated dose and pharmacokinetics/pharmacodynamics in heavily pretreated advanced breast cancer | Provide systemic therapy intended to control disease progression, personalized by biomarker profile and prior therapies |
| Evidence status | Early‑phase clinical evaluation; safety, tolerability, PK/PD data are being collected; efficacy in humans not yet established | Clinical benefit and survival prolongation supported by extensive evidence and consensus recommendations |
| Important limitations | Safety and efficacy are not yet established; dosing limits and toxicity profile remain unknown in humans | Treatment choice may be limited by prior therapies, biomarker resistance, organ function or CNS metastases |
| Patient impact | Undetermined – investigational; patient benefit not yet shown in trials | Proven capacity to control disease, prolong survival, and maintain quality of life in suitable patients |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - At least 21 days, may continue longer if safe and effective
Participants take MBQ-167 capsules orally twice daily, starting with doses between 10mg and 400mg. Dosing continues at safe and effective levels until stopping criteria are met.
Multiple visits for evaluations and laboratory tests
Duration - Varies by participant until study end or discontinuation
Participants continue visits including laboratory tests and diary reviews until after they stop taking the study drug.
Regular visits for safety and response monitoring
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Luis D Borrero-García, Maria Del Mar Maldonado, Julia Medina-Velázquez...
https://pubmed.ncbi.nlm.nih.gov/34074257/Tessa Humphries-Bickley, Linette Castillo-Pichardo, Eliud Hernandez-O'Farrill...
https://pubmed.ncbi.nlm.nih.gov/28450422/Ailed Cruz-Collazo, Jean F Ruiz-Calderon, Hector Picon...
https://pubmed.ncbi.nlm.nih.gov/34607932/Julia I Medina, Ailed Cruz-Collazo, Maria Del Mar Maldonado...
https://pubmed.ncbi.nlm.nih.gov/36861094/Anamaris Torres-Sanchez, Michael Rivera-Robles, Linette Castillo-Pichardo...
https://pubmed.ncbi.nlm.nih.gov/37397366/María Del Mar Maldonado, Suranganie Dharmawardhane
https://pubmed.ncbi.nlm.nih.gov/29858187/MBQ Pharma
Lead Sponsor
Congressionally Directed Medical Research Programs
Collaborating Sponsor